Interferon-β treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity

AIMS: To determine CYP2C19 and CYP2D6 activity in patients with multiple sclerosis (MS) before and during interferon (IFN)-β treatment. METHODS: CYP2C19 and CYP2D6 activities were assessed using the probe drugs mephenytoin and debrisoquine, respectively. Urinary mephenytoin (S/R) and debrisoquine (d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hellman, Karin, Roos, Ewa, Österlund, Anna, Wahlberg, Anneli, Gustafsson, Lars L, Bertilsson, Leif, Fredrikson, Sten
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2003
Assuntos:
Short Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1884353/
https://ncbi.nlm.nih.gov/pubmed/12919185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.0306-5251.2003.01859.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados